Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06976736 · ClinicalTrials.gov registry record
A Long Term Follow-up Study of TScan TCR-T Products
A clinical trial of AML and MDS, sponsored by TScan Therapeutics.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 2
- Study locations
NCT06976736: Recruiting study of AML and MDS, sponsored by TScan Therapeutics.
NCT06976736 is a study of AML and MDS that is actively recruiting participants, run by TScan Therapeutics. The registered enrollment target is 1,000 participants, above the 99-participant average among 29 other AML trials with a reported enrollment target (910% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06976736, a study of AML and MDS, is actively recruiting participants, sponsored by TScan Therapeutics.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study. Participants will be monitored for 15 years from the date of TCR-T cell therapy administration to assess long-term safety and efficacy.
Primary Outcome
To assess the long-term safety of TSC-100 and TSC-101 in participants by evaluating the incidence, duration, and outcome of adverse events and adverse events of special interest.
Interventions
- OTHER Observational
Study Locations (2)
California
- City of Hope - Duarte
New York
- Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-09-09 |
| Est. Completion | 2040-09 |
What NCT06976736 shows while recruiting
NCT06976736 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 99-participant average among 29 other AML trials with a reported enrollment target (910% higher).
The record links to 3 conditions, with AML appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.
NCT06976736 reports a single indexed study location in California, New York.
Frequently Asked Questions
What is clinical trial NCT06976736 about?
NCT06976736 is a clinical study titled "A Long Term Follow-up Study of TScan TCR-T Products". The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study. Participants will be monitored for 15 years from the date of TCR-T cell therapy administration to assess long-term safety and effica...
What is the current status of trial NCT06976736?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-09-09. Estimated completion is 2040-09.
What conditions does trial NCT06976736 study?
This clinical trial studies the following conditions: AML, MDS, ALL.
What interventions are being tested in trial NCT06976736?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT06976736?
This trial is sponsored by TScan Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06976736 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AML
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06976736's enrollment target sits among peer trials
1,000 2nd of 29 the highest of 29 other AML trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other AML trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RECRUITING
-
Familial Investigations of Childhood Cancer Predisposition
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI